Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STN1010904
- Development stage
- Phase 2
- Lead developer
- Santen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
STN1010904 is an investigational ophthalmic suspension of sirolimus, a small molecule mTOR inhibitor, being developed by Santen in collaboration with ActualEyes for the treatment of Fuchs endothelial corneal dystrophy (FECD). The drug works by suppressing corneal endothelial cell apoptosis, thereby decelerating the progression of the disease. It is currently being evaluated in the Phase 2a PHANTOM study, which tests 0.03% and 0.1% concentrations administered twice daily. FECD is a degenerative condition of the corneal endothelium that currently lacks pharmacological treatments and often necessitates corneal transplantation. STN1010904 represents a potential first-in-class pharmaceutical therapy for this condition.
- Other names
- sirolimus ophthalmic suspension
02
Targets
Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on STN1010904.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STN1010904.